Generating Paclitaxel-Resistant in Cervical Cancer HeLa Cell Line
Cervical cancer is one of the most leading causes of women death. Currently, paclitaxel is still one of the main therapeutic regimens for cervical cancer patients. However, some patients developed to be paclitaxel-resistant. Hence, studies to find out the novel strategies to resolve this problem are...
Main Authors: | Muhammad Hasan Bashari, Fachreza Aryo Damara, Isna Nisrina Hardani, Gita Widya Pradini, Tenny Putri, Eko Fuji Ariyanto |
---|---|
Format: | Article |
Language: | English |
Published: |
Indonesian Society for Cancer Chemoprevention
2020-07-01
|
Series: | ISCC (Indonesian Journal of Cancer Chemoprevention) |
Online Access: | https://ijcc.chemoprev.org/index.php/ijcc/article/view/318 |
Similar Items
-
Combination of SAHA and Paclitaxel Induce Apoptosis of Human Cervical Cancer HeLa Cells
by: ZHANG Lei, et al.
Published: (2018-06-01) -
HeLa Cell-Derived Paclitaxel-Loaded Microparticles Efficiently Inhibit the Growth of Cervical Carcinoma
by: Peng J, et al.
Published: (2020-08-01) -
Effect of Gallic acid in potentiating chemotherapeutic effect of Paclitaxel in HeLa cervical cancer cells
by: Nora M. Aborehab, et al.
Published: (2019-06-01) -
Closing of postoperative integument, skull bones, and dura defects
by: Fachreza Aryo Damara
Published: (2020-01-01) -
Factors influencing the outcome of necrotizing fasciitis
by: Fachreza Aryo Damara, et al.
Published: (2021-01-01)